Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Pegaspargase and Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

This study has been terminated.
(Increased rate of bacterial infections)
Sponsor:
Collaborator:
Information provided by (Responsible Party):
OHSU Knight Cancer Institute
ClinicalTrials.gov Identifier:
NCT01005914
First received: October 30, 2009
Last updated: February 9, 2015
Last verified: February 2015

October 30, 2009
February 9, 2015
June 2009
March 2013   (final data collection date for primary outcome measure)
  • Complete Response Rate After Course 1 of Pegaspargase When Administered in Combination With Hyper-CVAD Regimen [ Time Frame: After day 4 of treatment ] [ Designated as safety issue: No ]
    The complete response rate after 1A cycle of a PEG-Asparaginase and hyper-CVAD combination regimen will be estimated, and an exact 95% confidence interval will be computed using a binomial distribution.
  • Grade 3 and 4 Toxicity Associated With the Combination of Peg-Asparaginase and Hyper-CVAD Which Include: Allergic Reactions, Elevated Liver Enzymes, Hyperbilirubinemia, Hyperglycemia, Central Nervous System (CNS) Thrombosis, and Pancreatitis. [ Time Frame: The assessment of safety will be based mainly on the frequency of adverse events ] [ Designated as safety issue: Yes ]
  • Complete response rate after course 1 of pegaspargase when administered in combination with hyper-CVAD regimen [ Designated as safety issue: No ]
  • Toxicity [ Designated as safety issue: Yes ]
Complete list of historical versions of study NCT01005914 on ClinicalTrials.gov Archive Site
  • 2-year Progression-free Survival [ Time Frame: After completion of 8 cycles ] [ Designated as safety issue: No ]
  • Proportion of Patients Who Achieve Complete Response or Partial Response After Courses 1 and 2 [ Time Frame: An interim analysis of safety is planned after the enrollment of 15 evaluable patients. ] [ Designated as safety issue: No ]
  • Overall Survival [ Time Frame: At least every 6 months until death. ] [ Designated as safety issue: No ]
  • Rate of Minimal Residual Disease [ Time Frame: End of cycles 1A and 1B ] [ Designated as safety issue: No ]
    Cycle 1A: Days 1 through 14 Cycle 1B: Days 1 through 8, after the first 14 days of cycle 1A
  • Half-life of Pegaspargase [ Time Frame: The approximate t½ in adult patients is 5.73 days. The half-life is independent of the dose administered, disease status, renal or hepatic function, age, or gender. ] [ Designated as safety issue: No ]
  • 2-year progression-free survival [ Designated as safety issue: No ]
  • Proportion of patients who achieve complete response or partial response after courses 1 and 2 [ Designated as safety issue: No ]
  • Overall survival [ Designated as safety issue: No ]
  • Rate of minimal residual disease [ Designated as safety issue: No ]
  • Half-life of pegaspargase [ Designated as safety issue: No ]
Not Provided
Not Provided
 
Pegaspargase and Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
Phase II Trial of the Addition of PEG-Asparaginase to the Hyper-CVAD Regimen in Adult Newly-Diagnosed Acute Lymphoblastic Leukemia

RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells.

PURPOSE: This phase II trial is studying the side effects of giving pegaspargase together with combination chemotherapy and to see how well it works in treating patients with newly diagnosed acute lymphoblastic leukemia.

OBJECTIVES:

Primary

  • To estimate the complete response rate in patients with newly diagnosed acute lymphoblastic leukemia treated with pegaspargase in combination with hyper-CVAD regimen comprising cyclophosphamide, dexamethasone, vincristine sulfate, doxorubicin hydrochloride, methotrexate, and cytarabine.
  • To determine the safety and tolerability of this regimen in these patients.

Secondary

  • To evaluate the progression-free survival and overall survival of patients treated with this regimen.
  • To determine the half-life of pegaspargase when administered in combination with hyper-CVAD regimen.
  • To monitor the development of neutralizing antibodies to pegaspargase when administered in combination with hyper-CVAD regimen.
  • To assess minimal residual disease by flow cytometry at the end of courses 1A and 1B.

OUTLINE: This is a multicenter study.

  • Hyper-CVAD regimen (courses 1, 3, 5, and 7): Patients receive cyclophosphamide IV over 2-3 hours twice daily on days 1-3, dexamethasone IV on days 1-4 and 11-14, methotrexate intrathecally (IT) on day 2, doxorubicin hydrochloride IV over 2 hours and pegaspargase IV over 1-2 hours on day 4, vincristine sulfate IV on days 4 and 11, and cytarabine IT on day 8.
  • High-dose methotrexate/cytarabine regimen (courses 2, 4, 6, and 8): Patients receive methotrexate IV continuously over 24 hours on day 1, methylprednisolone IV twice daily on days 1-3, methotrexate IT on day 2, cytarabine IV over 2 hours twice daily on days 2 and 3, pegaspargase IV over 1-2 hours on day 3, and cytarabine IT on day 8.

Treatment repeats every 3-4 weeks for 8 courses in the absence of disease progression or unacceptable toxicity. Patients with Philadelphia chromosome-positive disease also receive oral imatinib mesylate daily beginning at diagnosis.

Patients who complete 8 courses of chemotherapy and are not candidates for hematopoietic stem cell transplantation receive maintenance therapy off study.

Blood samples are collected at baseline and periodically during study for pharmacokinetics and neutralizing antibody assays.

After completion of study therapy, patients are followed up every 6 months.

Interventional
Phase 2
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Leukemia
  • Drug: cyclophosphamide
    Day 1- 3: 300 m g/m2 IV over 2-3 hours every 12 hours for 6 doses plus mesna 600 mg/ m2 /day continuous infusion Days 1-3
    Other Name: Cytoxan, Neosar, CTX
  • Drug: cytarabine
    Day 2 & 3: 3g/m2 IV over 2 hours q12 X 4
    Other Name: Cytosar-U, Ara-C, Arabinosylcytosine
  • Drug: dexamethasone
    Day 1-4; 11-14: 40 mg daily
    Other Name: Decadron, DexPak, dex
  • Drug: doxorubicin hydrochloride
    Day 4: 50 mg/m2 IV over 2 hours
    Other Name: Adriamycin RDF, Adriamycin PFS
  • Drug: imatinib mesylate
    600 mg/day
    Other Name: Gleevec, Glivec
  • Drug: methotrexate
    Day 1: 1g/ m2 (200 mg/ m2load IV over 2 hours plus 800 mg/ m2 over 22 hours as an infusion
    Other Name: Trexall, Rheumatrex, MTX
  • Drug: methylprednisolone
    Day 1-3: 50mg IV BID
    Other Name: Medrol, Depo-Medrol, Solu-Medrol
  • Drug: pegaspargase
    Day 3/Day4: 2,500 IU/ m2 IV
    Other Name: Onscapar, PEG-L-asparaginase
  • Drug: vincristine sulfate
    Day 4 & 11: 2 mg IV
    Other Name: Marqibo
Experimental: Group 1

Drug:cyclophosphamide Day 1- 3: 300 m g/m2 IV over 2-3 hours every 12 hours for 6 doses plus mesna 600 mg/ m2 /day continuous infusion Days 1-3

Drug:cytarabine Day 2 & 3: 3g/m2 IV over 2 hours q12 X 4

Drug:dexamethasone Day 1-4; 11-14: 40 mg daily

Drug:doxorubicin hydrochloride Day 4: 50 mg/m2 IV over 2 hours

Drug:imatinib mesylate 600 mg/day

Drug:methotrexate Day 1: 1g/ m2 (200 mg/ m2load IV over 2 hours plus 800 mg/ m2 over 22 hours as an infusion

Drug: methylprednisolone Day 1-3: 50mg IV BID

Drug: pegaspargase Day 3/Day4: 2,500 IU/ m2 IV

Drug: vincristine sulfate Day 4 & 11: 2 mg IV

Interventions:
  • Drug: cyclophosphamide
  • Drug: cytarabine
  • Drug: dexamethasone
  • Drug: doxorubicin hydrochloride
  • Drug: imatinib mesylate
  • Drug: methotrexate
  • Drug: methylprednisolone
  • Drug: pegaspargase
  • Drug: vincristine sulfate
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
11
May 2014
March 2013   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patients must be newly diagnosed (untreated) with Acute Lymphoblastic Leukemia based on a bone marrow examination unless there is a contraindication to having the test performed. This includes precursor-B ALL, precursor-T ALL, and Philadelphia chromosome positive ALL. For reference, see criteria by Center for International Blood and Marrow Transplant Research (CIBMTR).> 20% blasts on a bone marrow aspirate OR If a bone marrow aspirate is not obtained, the diagnosis of acute leukemia can be established by a pathologic diagnosis of acute leukemia on a bone marrow biopsy OR A complete blood count documenting the presence of at least 10,000 white blood cells (WBC)/μl and at least 20% circulating blasts
  • Adults, 18 to 60 years of age.
  • Women of child bearing potential (WOCBP) must be willing to use adequate contraception to avoid pregnancy for the duration of study participation.
  • Eastern Cooperative Oncology Group (ECOG) performance status < 2
  • Adequate renal function defined as: Serum creatinine ≤ 2.0 x upper limit normal (ULN) for institution
  • Adequate hepatic function defined as:Total bilirubin ≤ 2.0 x ULN for institution Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.0 x ULN for institution
  • Patient must have the ability to understand and the willingness to sign a written informed consent document. The patient and/or the patient's legally authorized guardian must acknowledge consent for treatment as a human subject on this study.

Exclusion Criteria:

  • Mature B (Burkitt's) ALL will be excluded.
  • An active malignancy other than ALL (with the exception of basal and/or squamous cell skin cancers and curatively treated carcinoma of the cervix) within 5 past years of study entry.
  • Documented central nervous system (CNS) involvement with leukemia will be excluded. A diagnostic lumbar puncture will not be part of screening procedures.
  • Severe pulmonary, renal, or hepatic disease not related to the patient's ALL will be excluded.
  • Cardiac dysfunction as defined by:Myocardial infarction within the last 6 months of study entry, or Reduced left ventricular function with an ejection fraction ≤50% as measured by Multigated Acquisition (MUGA) scan or echocardiogram at study entry, Unstable angina, Unstable cardiac arrhythmias, New York Heart Association (NYHA) Class III or IV heart failure, Electrocardiographic evidence of acute ischemia or active conduction system abnormalities
  • Known or suspected human immunodeficiency virus (HIV)-positive patients are excluded from the study because of possible risk of lethal infection when treated with marrow suppressive therapy.
  • Any concurrent severe and/or uncontrolled medical condition (e.g. uncontrolled diabetes, infection, hypertension, etc.) or psychiatric illness that could, in the investigator's opinion, potentially interfere with the completion of treatment according to this protocol.
  • Patients who have had chemotherapy or radiotherapy for ALL prior to entering the study will be excluded. Hydroxyurea and one dose of intravenous vincristine are allowed prior to registration for patient convenience. Prior steroid therapy is allowable, ≤5 days prior to the start of the regimen.
  • Patients may not have received any other investigational agents within the last 30 days.
  • WOCBP who are unwilling or unable to use an acceptable method of contraception for the entire study period. Pregnant or lactating women are excluded from this study because of possible risk to the fetus or infant. Women with a positive serum pregnancy test on enrollment or prior to study drug administration will be excluded.
  • Men whose sexual partners are WOCBP, who are unwilling or unable to use an acceptable contraceptive method to avoid pregnancy of his partner for the entire study period.
Both
18 Years to 60 Years
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01005914
CDR0000642363, P30CA069533, OHSU-4913, ENZON-OHSU-4913
Yes
OHSU Knight Cancer Institute
OHSU Knight Cancer Institute
National Cancer Institute (NCI)
Principal Investigator: Brandon Hayes-Lattin OHSU Knight Cancer Institute
OHSU Knight Cancer Institute
February 2015

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP